Cross-topic event
Revolution Medicines oral KRAS inhibitor daraxonrasib phase 3: median OS 13.2 vs. 6.7 months in metastatic pancreatic cancer
Jun 20, 20262 reports
Jun 20, 2026
Sciencedesk view
Revolution Medicines oral KRAS inhibitor daraxonrasib phase 3: median OS 13.2 vs. 6.7 months in metastatic pancreatic cancer
Per AOL on June 20, 2026, and phase 3 results in The New England Journal of Medicine, Revolution Medicines' oral KRAS inhibitor daraxonrasib in ~500 randomized …
READ THE DAY'S DIGEST →
Sports/Healthdesk view
Phase 3 Trial: Pancreatic Cancer Pill Daraxonrasib Doubles Median Survival
Per AOL on June 20, a 500-patient Phase 3 trial published in The New England Journal of Medicine found oral KRAS inhibitor daraxonrasib for metastatic pancreati…
READ THE DAY'S DIGEST →